PHARMOS's operating cash flow stood at CZK 7.52 mil in 2019, down 95.7% when compared to the previous year. Historically, between 2006 - 2019, the firm’s operating cash flow reached a high of CZK 177 mil in 2018 and a low of CZK -147 mil in 2013.
PHARMOS's total investments stood at CZK 3.28 mil and accounted for 0.125% of sales in 2019. This is compared to an average of 0.630% as seen over the last five years.
Cash from financing amounted to CZK -46.1 mil, so the company generated CZK 14.7 mil net cash in 2019.
At the end of 2019, the company had a net debt of CZK 1,245 mil, or 21.7x of EBITDA and 191% of equity. Net working capital amounted to CZK 1,745 mil, or 16.9% of sales. Cash conversion cycle is negative and reached 61.2 days days in 2019. This means PHARMOS generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at PHARMOS profile, or you can download a report on the company in the report section.
Helgi Library 
